Development of a Cystic Fibrosis Population Model for Physiologically Based Pharmacokinetic Models: Is It Worth It?
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis.
Sanders M, Hong E, Chung P, Rao A, Beringer P Clin Pharmacokinet. 2024; 63(12):1701-1709.
PMID: 39581957 PMC: 11649715. DOI: 10.1007/s40262-024-01440-w.
References
1.
Szentpetery S, Fernandez G, Schechter M, Jain R, Flume P, Fink A
. Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry. J Cyst Fibros. 2022; 21(5):777-783.
PMC: 9509402.
DOI: 10.1016/j.jcf.2022.03.010.
View
2.
Hong E, Almond L, Chung P, Rao A, Beringer P
. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19. Clin Pharmacol Ther. 2022; 111(6):1324-1333.
PMC: 9087007.
DOI: 10.1002/cpt.2585.
View
3.
Amiel M, Ke A, Gelone S, Jones H, Wicha W
. Physiologically-based pharmacokinetic modeling of the drug-drug interaction between ivacaftor and lefamulin in cystic fibrosis patients. CPT Pharmacometrics Syst Pharmacol. 2024; 13(4):589-598.
PMC: 11015074.
DOI: 10.1002/psp4.13103.
View
4.
Carnovale V, Scialo F, Gelzo M, Iacotucci P, Amato F, Zarrilli F
. Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment. J Clin Med. 2022; 11(23).
PMC: 9735556.
DOI: 10.3390/jcm11236900.
View
5.
De Sutter P, Van Haeverbeke M, Van Braeckel E, Van Biervliet S, Van Bocxlaer J, Vermeulen A
. Altered intravenous drug disposition in people living with cystic fibrosis: A meta-analysis integrating top-down and bottom-up data. CPT Pharmacometrics Syst Pharmacol. 2022; 11(8):951-966.
PMC: 9381904.
DOI: 10.1002/psp4.12832.
View